Radionuclide Imaging for Neuroscience: Current Opinion and Future Directions

This meeting report summarizes a Consultants Meeting that was held at International Atomic Energy Agency headquarters in Vienna to provide an update on radionuclide imaging for neuroscience applications.

[1]  Eric Berg,et al.  Development and Evaluation of mini-EXPLORER: A Long Axial Field-of-View PET Scanner for Nonhuman Primate Imaging , 2018, The Journal of Nuclear Medicine.

[2]  Ephraim E. Parent,et al.  Training the next generation of radiopharmaceutical scientists. , 2020, Nuclear medicine and biology.

[3]  Victor W Pike,et al.  PET radiotracers: crossing the blood-brain barrier and surviving metabolism. , 2009, Trends in pharmacological sciences.

[4]  Antony D. Gee,et al.  Small Molecules as Radiopharmaceutical Vectors , 2019 .

[5]  C. Nahmias,et al.  The effect of aromatic fluorine substitution in l-DOPA on the in vivo behaviour of [18F]2-, [18F]5- and [18F]6-fluoro-l-DOPA in the human brain☆ , 2002 .

[6]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[7]  Markus Piel,et al.  Positron emission tomography in CNS drug discovery and drug monitoring. , 2014, Journal of medicinal chemistry.

[8]  Pengcheng Hu,et al.  First Human Imaging Studies with the EXPLORER Total-Body PET Scanner* , 2019, The Journal of Nuclear Medicine.

[9]  Joel S Karp,et al.  Total-body imaging: Transforming the role of positron emission tomography , 2017, Science Translational Medicine.

[10]  Craig K. Abbey,et al.  High-throughput in vivo screening of targeted molecular imaging agents , 2009, Proceedings of the National Academy of Sciences.

[11]  K. Kirk.  Fluorination in Medicinal Chemistry: Methods, Strategies, and Recent Developments , 2008 .

[12]  G. Knudsen,et al.  Development and Evaluation of Two Potential 5-HT7 Receptor PET Tracers: [18F]ENL09 and [18F]ENL10. , 2019, ACS chemical neuroscience.

[13]  S. G. Patching.  Roles of facilitative glucose transporter GLUT1 in ( 18 F)FDG positron emission tomography (PET) imaging of human diseases , 2015 .

[14]  J. Hooker,et al.  A Philosophy for CNS Radiotracer Design , 2014, Accounts of chemical research.

[15]  G. Knudsen,et al.  Accelerating preclinical PET-screening: reductive amination with [11C]methoxybenzaldehydes , 2014 .

[16]  W. Moses,et al.  Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care , 2018, The Journal of Nuclear Medicine.

[17]  Steven H. Liang,et al.  Total Radiosynthesis: Thinking outside "the box". , 2015, Australian journal of chemistry.

[18]  Obaidur Rahman,et al.  [11C]Carbon monoxide, a versatile and useful precursor in labelling chemistry for PET‐ligand development , 2007 .

[19]  Steven H. Liang,et al.  Facile 18F labeling of non-activated arenes via a spirocyclic iodonium(III) ylide method and its application in the synthesis of the mGluR5 PET radiopharmaceutical [18F]FPEB , 2019, Nature Protocols.

[20]  Discovery of PET radiopharmaceuticals at the academia-industry interface. , 2017, Drug discovery today. Technologies.

[21]  S. Kinomura,et al.  Parametric mapping of cerebral blood flow deficits in Alzheimer's disease: a SPECT study using HMPAO and image standardization technique. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[23]  D. Aarsland,et al.  ( I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study , 2013 .